IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab

References

• LabiancaRBerettaGDKildaniBColon cancerCrit Rev Oncol Hematol201074210613320138539
   PubMed Web of Science ®Google Scholar
• DahabrehIJTerasawaTCastaldiPJTrikalinosTASystematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancerAnn Intern Med20111541374921200037
   PubMed Web of Science ®Google Scholar
• EllisLMHicklinDJPathways mediating resistance to vascular endothelial growth factor-targeted therapyClin Cancer Res200814206371637518927275
   PubMed Web of Science ®Google Scholar
• WillettCGDudaDGdi TomasoEEfficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II studyJ Clin Oncol200927183020302619470921
   PubMed Web of Science ®Google Scholar
• KopetzSHoffPMMorrisJSPhase II trial of infusional fluo-rouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistanceJ Clin Oncol201028345345920008624
   PubMed Web of Science ®Google Scholar
• LoupakisFCremoliniCFioravantiAPharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancerBr J Cancer201110481262126921407216
   PubMed Web of Science ®Google Scholar
• LieuCHTranHJiangZQThe association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancerPLoS One2013810e7711724143206
   PubMed Web of Science ®Google Scholar
• AbajoABoniVLopezIIdentification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patientsBr J Cancer2012107228729022699823
   PubMed Web of Science ®Google Scholar
• WallynFA prospective study of innovative non-invasive tools to assess the response to anti-angiogenic therapies in non small cell lung cancer patientsIASLC2013
   Google Scholar
• BackenARenehanAGClampARThe combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancerClin Cancer Res201420174549455824947924
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTEHudesGRInvestigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinomaCancer Chemother Pharmacol201474473975025100134
   PubMed Web of Science ®Google Scholar
• van CutsemETaberneroJLakomyRAddition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimenJ Clin Oncol201230283499350622949147
   PubMed Web of Science ®Google Scholar
• JubbAMMillerKDRugoHSImpact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancerClin Cancer Res201117237238121224365
   PubMed Web of Science ®Google Scholar
• PassardiANanniOTassinariDEffectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trialAnn Oncol20152661201120725735317
   PubMed Web of Science ®Google Scholar
• di SalvatoreMPietrantonioFOrlandiAIL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patientsOncotarget2017810168871689828129643
   PubMedGoogle Scholar
• TaguchiAOhmiyaNShiraiKInterleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in JapanCancer Epidemiol Biomarkers Prev20051411 Pt 12487249316284368
   PubMed Web of Science ®Google Scholar
• HildebrandFStuhrmannMvan GriensvenMAssociation of IL-8-251A/T polymorphism with incidence of acute respiratory distress syndrome (ARDS) and IL-8 synthesis after multiple traumaCytokine200737319219917498967
   PubMed Web of Science ®Google Scholar
• HullJThomsonAKwiatkowskiDAssociation of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK familiesThorax200055121023102711083887
   PubMed Web of Science ®Google Scholar
• KochAEPolveriniPJKunkelSLInterleukin-8 as a macrophage-derived mediator of angiogenesisScience19922585089179818011281554
   PubMed Web of Science ®Google Scholar
• VarneyMLOlsenKJMosleyRLBucanaCDTalmadgeJESinghRKMonocyte/macrophage recruitment, activation and differentiation modulate interleukin-8 production: a paracrine role of tumor-associated macrophages in tumor angiogenesisIn Vivo200216647147712494891
   PubMed Web of Science ®Google Scholar
• RamanDBaugherPJThuYMRichmondARole of chemokines in tumor growthCancer Lett2007256213716517629396
   PubMed Web of Science ®Google Scholar
• XieKInterleukin-8 and human cancer biologyCytokine Growth Factor Rev200112437539111544106
   PubMed Web of Science ®Google Scholar
• MaedaKNishiguchiYYashiroMExpression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinomaInt J Mol Med20005437337810719053
   PubMed Web of Science ®Google Scholar
• BrostjanCGebhardtKGruenbergerBNeoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levelsClin Cancer Res20081472065207418381946
   PubMed Web of Science ®Google Scholar
• GodiskaRChantryDRaportCJHuman macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cellsJ Exp Med19971859159516049151897
   PubMed Web of Science ®Google Scholar
• LiADubeySVarneyMLDaveBJSinghRKIL-8 directly enhanced endothelial cell survival, proliferation, and matrix metal-loproteinases production and regulated angiogenesisJ Immunol200317063369337612626597
   PubMed Web of Science ®Google Scholar
• BüngerSHaugUKellyFMToward standardized high-throughput serum diagnostics: multiplex-protein array identifies IL-8 and VEGF as serum markers for colon cancerJ Biomol Screen20111691018102621807963
   PubMedGoogle Scholar
• GoedeVCoutelleONeuneierJIdentification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapyBr J Cancer201010391407141420924372
   PubMed Web of Science ®Google Scholar
• LiuYStarrMDBulusuACorrelation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumabCancer Med20132223424223634291
   PubMed Web of Science ®Google Scholar
• KasebAOGarrett-MayerEMorrisJSEfficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trialOncology2012822677422327795
   PubMed Web of Science ®Google Scholar
• LabussièreMCheneauCPrahstCAngiopoietin-2 may be involved in the resistance to bevacizumab in recurrent glioblastomaCancer Invest2016341394426735326
   PubMed Web of Science ®Google Scholar
• LamSWNotaNMJagerAAngiogenesis- and hypoxia-associated proteins as early indicators of the outcome in patients with metastatic breast cancer given first-line bevacizumab-based therapyClin Cancer Res20162271611162026823602
   PubMed Web of Science ®Google Scholar
• Pogue-GeileKYothersGTaniyamaYDefective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08J Natl Cancer Inst20131051398999223821759
   PubMedGoogle Scholar
• UliviPScarpiEChiadiniERight- vs. left-sided metastatic colorectal cancer: differences in tumor biology and bevacizumab efficacyInt J Mol Sci20171861240
   PubMed Web of Science ®Google Scholar
• VenookAPNiedzwieckiDInnocentiFImpact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (alliance)J Clin Oncol20163415 Suppl3504
   Google Scholar